The Experts below are selected from a list of 249 Experts worldwide ranked by ideXlab platform
Peter Wust - One of the best experts on this subject based on the ideXlab platform.
-
hyperthermia related clinical trials on cancer treatment within the clinicaltrials gov registry
International Journal of Hyperthermia, 2015Co-Authors: Nikola Cihoric, Jacek Nadobny, Alexandros Tsikkinis, Gerard C Van Rhoon, Hans Crezee, Daniel M Aebersold, Stephan Bodis, Marcus Beck, Volker Budach, Peter WustAbstract:AbstractPurpose: Hyperthermia has been shown to improve the effectiveness of chemotherapy and radiotherapy in the treatment of cancer. This paper summarises all recent clinical trials registered in the ClinicalTrials.gov registry. Materials and methods: The records of 175,538 clinical trials registered at ClinicalTrials.gov were downloaded on 29 September 2014 and a database was established. We searched this database for hyperthermia or equivalent words. Results: A total of 109 trials were identified in which hyperthermia was part of the treatment regimen. Of these, 49 trials (45%) had Hyperthermic intraperitoneal chemotherapy after cytoreductive surgery (HIPEC) as the primary intervention, and 14 other trials (13%) were also testing some form of intraperitoneal Hyperthermic chemoperfusion. Seven trials (6%) were testing perfusion attempts to other locations (thoracic/pleural n = 4, limb n = 2, hepatic n = 1). Sixteen trials (15%) were testing regional hyperthermia, 13 trials (12%) whole body hyperthermia...
-
Standards and perspectives in locoregional hyperthermia
Wiener medizinische Wochenschrift (1946), 2004Co-Authors: Bert Hildebrandt, J. Gellermann, Beate Rau, Thoralf Kerner, Annett Nicolaou, Jens-uwe Blohmer, Ralf Ulrich Trappe, Hanno Riess, Peter WustAbstract:The term "hyperthermia" summarises different procedures of raising the temperature of a tumour-loaded tissue to a temperature of 40-43 degrees C. In this context, locoregional procedures (radiative/capacitive local, interstitial and regional hyperthermia; endoluminal hyperthermia), Hyperthermic perfusion techniques (Hyperthermic peritoneal and isolated limb perfusion), and whole-body hyperthermia differ with regard to their indication, expenditure of application, and evidence of efficacy. All hyperthermia techniques have in common that they have no sufficient antineoplastic activity alone in the temperature range below 43-45 degrees C, but act in a synergistic way with radiotherapy and certain cytotoxic drugs. 14 out of 18 published randomised trials on hyperthermia as an adjunct to standard radio- or chemotherapy refer to locoregional approaches. Particular progress has been made in regional radiofrequency hyperthermia, where novel multiantenna-applicators and their integration into MR-applicators ("hybrid-systems") have recently been introduced into clinical practice. In addition, combinations of hyperthermia with novel technologies (magnetic fluid hyperthermia, thermosensitive liposomes, immunotherapy, gene targeting) are imminent. We here give a critical update on the proven indications of the different locoregional hyperthermia approaches and on the current clinical and technological progress in this field.
-
the cellular and molecular basis of hyperthermia
Critical Reviews in Oncology Hematology, 2002Co-Authors: Bert Hildebrandt, Thoralf Kerner, Peter Wust, Olaf Ahlers, Annette Dieing, Geetha Sreenivasa, R Felix, Hanno RiessAbstract:Abstract In oncology, the term ‘hyperthermia’ refers to the treatment of malignant diseases by administering heat in various ways. Hyperthermia is usually applied as an adjunct to an already established treatment modality (especially radiotherapy and chemotherapy), where tumor temperatures in the range of 40–43 °C are aspired. In several clinical phase-III trials, an improvement of both local control and survival rates have been demonstrated by adding local/regional hyperthermia to radiotherapy in patients with locally advanced or recurrent superficial and pelvic tumors. In addition, interstitial hyperthermia, Hyperthermic chemoperfusion, and whole-body hyperthermia (WBH) are under clinical investigation, and some positive comparative trials have already been completed. In parallel to clinical research, several aspects of heat action have been examined in numerous pre-clinical studies since the 1970s. However, an unequivocal identification of the mechanisms leading to favorable clinical results of hyperthermia have not yet been identified for various reasons. This manuscript deals with discussions concerning the direct cytotoxic effect of heat, heat-induced alterations of the tumor microenvironment, synergism of heat in conjunction with radiation and drugs, as well as, the presumed cellular effects of hyperthermia including the expression of heat-shock proteins (HSP), induction and regulation of apoptosis, signal transduction, and modulation of drug resistance by hyperthermia.
-
The cellular and molecular basis of hyperthermia.
Critical reviews in oncology hematology, 2002Co-Authors: Bert Hildebrandt, Thoralf Kerner, Peter Wust, Olaf Ahlers, Annette Dieing, Geetha Sreenivasa, R Felix, Hanno RiessAbstract:In oncology, the term 'hyperthermia' refers to the treatment of malignant diseases by administering heat in various ways. Hyperthermia is usually applied as an adjunct to an already established treatment modality (especially radiotherapy and chemotherapy), where tumor temperatures in the range of 40-43 degrees C are aspired. In several clinical phase-III trials, an improvement of both local control and survival rates have been demonstrated by adding local/regional hyperthermia to radiotherapy in patients with locally advanced or recurrent superficial and pelvic tumors. In addition, interstitial hyperthermia, Hyperthermic chemoperfusion, and whole-body hyperthermia (WBH) are under clinical investigation, and some positive comparative trials have already been completed. In parallel to clinical research, several aspects of heat action have been examined in numerous pre-clinical studies since the 1970s. However, an unequivocal identification of the mechanisms leading to favorable clinical results of hyperthermia have not yet been identified for various reasons. This manuscript deals with discussions concerning the direct cytotoxic effect of heat, heat-induced alterations of the tumor microenvironment, synergism of heat in conjunction with radiation and drugs, as well as, the presumed cellular effects of hyperthermia including the expression of heat-shock proteins (HSP), induction and regulation of apoptosis, signal transduction, and modulation of drug resistance by hyperthermia.
Steven A Curley - One of the best experts on this subject based on the ideXlab platform.
-
the ongoing history of thermal therapy for cancer
Surgical Oncology Clinics of North America, 2011Co-Authors: Evan S Glazer, Steven A CurleyAbstract:Through 5,000 years of practice, physicians, surgeons, clergy, or lay people have utilized thermal therapy to treat mass lesions now known as cancer. The methods have changed dramatically over this time span and certainly the techniques have improved the efficacy and safety, but fundamentally, Hyperthermic therapy is usually a local or regional treatment for most cancer patients. Fortunately, hyperthermia used in combination with chemotherapy or ionizing radiation continues to improve outcomes. We will briefly describe the historic role of hyperthermia in cancer care as well as modern expectations based on technological advancements. In particular, we will focus on the role of hyperthermia for cancers that do not have other, more effective treatments.
-
targeted hyperthermia using metal nanoparticles
Advanced Drug Delivery Reviews, 2010Co-Authors: Paul Cherukuri, Evan S Glazer, Steven A CurleyAbstract:Despite the use of hyperthermia to treat cancer for thousands of years, the challenge of only heating malignant cells remains daunting. In pre-clinical and early clinical trials, metal nanoparticles induce Hyperthermic cytotoxicity when exposed to near-infrared radiation or radiofrequency fields. We discuss the emerging roles of nanoparticles, especially gold, in the Hyperthermic treatment of cancer. In addition, we discuss the similarities of radiofrequency ablation and nanoparticle mediated cytotoxicity.
Jacek Nadobny - One of the best experts on this subject based on the ideXlab platform.
-
Quality assurance guidelines for superficial hyperthermia clinical trials
Strahlentherapie und Onkologie, 2017Co-Authors: Hana Dobšíček Trefná, Johannes Crezee, Manfred Schmidt, Dietmar Marder, Ulf Lamprecht, Michael Ehmann, Jacek Nadobny, Josefin Hartmann, Nicolleta Lomax, Sultan Abdel-rahmanAbstract:Um eine einheitliche Durchführung klinischer Studien in der Hyperthermie zu gewährleisten, sind Leitlinien zur Qualitätssicherung (QA) unerlässlich. Dieses Dokument enthält die Anforderungen zur QA für alle aktuellen Therapiegeräte zur lokalen Hyperthermie, inklusive elektromagnetischer Systeme (radiativ und kapazitiv), Ultraschall- und Infrarottechnik. In detaillierten Anleitungen wird erklärt, wie die Leistungscharakteristik der Hyperthermieapplikatoren zu beschreiben und zu dokumentieren ist, um reproduzierbare, einheitliche und qualitativ hochwertige Hyperthermiebehandlungen zu gewährleisten. Im Gegensatz zu früheren Leitlinien wird anstelle der spezifischen Absorptionsrate (SAR) jetzt der Temperaturanstieg als maßgeblicher Parameter für die Beschreibung der Leistungscharakteristik von Hyperthermieapplikatoren verwendet. Grund für diesen Ansatz ist eine möglichst einfache und kostengünstige Leistungsbeschreibung. Diese ist notwendig, um für jeden einzelnen Applikator die maximale Tumorgröße und -tiefe zu bestimmen, die adäquat überwärmt werden kann. Dieses Dokument wird durch die Leitlinie zur klinischen Durchführung der lokalen Hyperthermie vervollständigt. Beide Teile der Leitlinie wurden vom Technischen Komitee der European Society for Hyperthermic Oncology (ESHO) in Zusammenarbeit mit leitenden Mitgliedern der Society of Thermal Medicine (STM) und Mitgliedern des Atzelsberger Kreises erarbeitet. Quality assurance (QA) guidelines are essential to provide uniform execution of clinical trials with uniform quality hyperthermia treatments. This document outlines the requirements for appropriate QA of all current superficial heating equipment including electromagnetic (radiative and capacitive), ultrasound, and infrared heating techniques. Detailed instructions are provided how to characterize and document the performance of these hyperthermia applicators in order to apply reproducible hyperthermia treatments of uniform high quality. Earlier documents used specific absorption rate (SAR) to define and characterize applicator performance. In these QA guidelines, temperature rise is the leading parameter for characterization of applicator performance. The intention of this approach is that characterization can be achieved with affordable equipment and easy-to-implement procedures. These characteristics are essential to establish for each individual applicator the specific maximum size and depth of tumors that can be heated adequately. The guidelines in this document are supplemented with a second set of guidelines focusing on the clinical application. Both sets of guidelines were developed by the European Society for Hyperthermic Oncology (ESHO) Technical Committee with participation of senior Society of Thermal Medicine (STM) members and members of the Atzelsberg Circle.
-
hyperthermia related clinical trials on cancer treatment within the clinicaltrials gov registry
International Journal of Hyperthermia, 2015Co-Authors: Nikola Cihoric, Jacek Nadobny, Alexandros Tsikkinis, Gerard C Van Rhoon, Hans Crezee, Daniel M Aebersold, Stephan Bodis, Marcus Beck, Volker Budach, Peter WustAbstract:AbstractPurpose: Hyperthermia has been shown to improve the effectiveness of chemotherapy and radiotherapy in the treatment of cancer. This paper summarises all recent clinical trials registered in the ClinicalTrials.gov registry. Materials and methods: The records of 175,538 clinical trials registered at ClinicalTrials.gov were downloaded on 29 September 2014 and a database was established. We searched this database for hyperthermia or equivalent words. Results: A total of 109 trials were identified in which hyperthermia was part of the treatment regimen. Of these, 49 trials (45%) had Hyperthermic intraperitoneal chemotherapy after cytoreductive surgery (HIPEC) as the primary intervention, and 14 other trials (13%) were also testing some form of intraperitoneal Hyperthermic chemoperfusion. Seven trials (6%) were testing perfusion attempts to other locations (thoracic/pleural n = 4, limb n = 2, hepatic n = 1). Sixteen trials (15%) were testing regional hyperthermia, 13 trials (12%) whole body hyperthermia...
Sultan Abdel-rahman - One of the best experts on this subject based on the ideXlab platform.
-
Quality assurance guidelines for superficial hyperthermia clinical trials
Strahlentherapie und Onkologie, 2017Co-Authors: Hana Dobšíček Trefná, Johannes Crezee, Manfred Schmidt, Dietmar Marder, Ulf Lamprecht, Michael Ehmann, Jacek Nadobny, Josefin Hartmann, Nicolleta Lomax, Sultan Abdel-rahmanAbstract:Um eine einheitliche Durchführung klinischer Studien in der Hyperthermie zu gewährleisten, sind Leitlinien zur Qualitätssicherung (QA) unerlässlich. Dieses Dokument enthält die Anforderungen zur QA für alle aktuellen Therapiegeräte zur lokalen Hyperthermie, inklusive elektromagnetischer Systeme (radiativ und kapazitiv), Ultraschall- und Infrarottechnik. In detaillierten Anleitungen wird erklärt, wie die Leistungscharakteristik der Hyperthermieapplikatoren zu beschreiben und zu dokumentieren ist, um reproduzierbare, einheitliche und qualitativ hochwertige Hyperthermiebehandlungen zu gewährleisten. Im Gegensatz zu früheren Leitlinien wird anstelle der spezifischen Absorptionsrate (SAR) jetzt der Temperaturanstieg als maßgeblicher Parameter für die Beschreibung der Leistungscharakteristik von Hyperthermieapplikatoren verwendet. Grund für diesen Ansatz ist eine möglichst einfache und kostengünstige Leistungsbeschreibung. Diese ist notwendig, um für jeden einzelnen Applikator die maximale Tumorgröße und -tiefe zu bestimmen, die adäquat überwärmt werden kann. Dieses Dokument wird durch die Leitlinie zur klinischen Durchführung der lokalen Hyperthermie vervollständigt. Beide Teile der Leitlinie wurden vom Technischen Komitee der European Society for Hyperthermic Oncology (ESHO) in Zusammenarbeit mit leitenden Mitgliedern der Society of Thermal Medicine (STM) und Mitgliedern des Atzelsberger Kreises erarbeitet. Quality assurance (QA) guidelines are essential to provide uniform execution of clinical trials with uniform quality hyperthermia treatments. This document outlines the requirements for appropriate QA of all current superficial heating equipment including electromagnetic (radiative and capacitive), ultrasound, and infrared heating techniques. Detailed instructions are provided how to characterize and document the performance of these hyperthermia applicators in order to apply reproducible hyperthermia treatments of uniform high quality. Earlier documents used specific absorption rate (SAR) to define and characterize applicator performance. In these QA guidelines, temperature rise is the leading parameter for characterization of applicator performance. The intention of this approach is that characterization can be achieved with affordable equipment and easy-to-implement procedures. These characteristics are essential to establish for each individual applicator the specific maximum size and depth of tumors that can be heated adequately. The guidelines in this document are supplemented with a second set of guidelines focusing on the clinical application. Both sets of guidelines were developed by the European Society for Hyperthermic Oncology (ESHO) Technical Committee with participation of senior Society of Thermal Medicine (STM) members and members of the Atzelsberg Circle.
O. Ott - One of the best experts on this subject based on the ideXlab platform.
-
Guideline for the clinical application, documentation and analysis of clinical studies for regional deep hyperthermia
Strahlentherapie und Onkologie, 2012Co-Authors: G. Bruggmoser, S. Bauchowitz, R. Canters, H. Crezee, M. Ehmann, J. Gellermann, U. Lamprecht, N. Lomax, M.b. Messmer, O. OttAbstract:Objectives These guidelines contain recommendations for the implementation of quality-assured hyperthermia treatments. The objective is to guarantee an internationally comparable and easily understandable method for hyperthermia treatment and for the subsequent scientific analysis of the treatment results. The guidelines describe “ regional deep hyperthermia” (RHT) and MR-controlled “ partial body hyperthermia” (PBH) of children, adolescents and adult patients. Hyperthermia in terms of these guidelines is defined as a treatment combining chemotherapy and/or radiation therapy. Methods These guidelines are based on practical experience from several hyperthermia centres in Europe. Our collaborative effort has ensured coordinated standards and quality control procedures in regional deep and partial body hyperthermia. The guidelines were developed by the Atzelsberg Research Group of the IAH (http://www.hyperthermie.org) of the German Cancer Society (“Deutsche Krebsgesellschaft”) to specifically ensure that the multi-institutional studies initiated by the Atzelsberg Research Group are executed following a single, uniform level of quality. Results The guidelines contain recommendations for procedural methods for treatment using hyperthermia. They commence with diagnosis, which is followed by preparation and treatment and concludes with standardised analysis for the reporting of results. Hintergrund Diese Leitlinie enthält Empfehlungen zur Durchführung von qualitätsgesicherten Hyperthermiebehandlungen. Ziel ist, ein vergleichbares und nachvollziehbares Vorgehen bei der Behandlung und der wissenschaftlichen Auswertung der Hyperthermie zu gewährleisten. Die Leitlinie beschreibt die „Regionale Tiefenhyperthermie“ (RHT) und die „MR-kontrollierte Teilkörperhyperthermie“ (PBH) von Kindern, Jugendlichen und erwachsenen Patienten. Die Hyperthermie im Sinne dieser Leitlinie wird als Kombinationsbehandlung mit einer Chemo- und/oder Strahlentherapie durchgeführt. Methodik Die vorgestellte Leitlinie basiert auf praktischen Erfahrungen von mehreren Hyperthermiezentren. Dieses Vorgehens erlaubt gemeinsam abgestimmte Standards in der Anwendung und der Qualitätskontrolle in der Hyperthermie für Studien, die im Rahmen des Atzelsberger Arbeitskreises in der Interdisziplinären Arbeitsgruppe Hyperthermie (http://www.hyperthermie.org) in der Deutschen Krebsgesellschaft und dem Technischen Komitee der „European Society for Hyperthermic Oncology“ (ESHO) entwickelt wurden, um sicher zu stellen, dass multizentrische Studien, die vom Atzelsberger Arbeitskreis entwickelt wurden, nach einem standardisierten, einheitlichen Qualitätsmaßstab durchgeführt werden. Ergebnisse Diese Leitlinie enthält Empfehlungen für das Vorgehen bei Hyperthermiebehandlungen von der Indikationsstellung, der Vorbereitung, der Durchführung bis zur standardisierten Auswertung. Die deutschsprachige Version des Beitrags ist auf SpringerLink unter „Supplemental“ zu finden.
-
Quality assurance for clinical studies in regional deep hyperthermia
Strahlentherapie und Onkologie, 2011Co-Authors: G. Bruggmoser, S. Bauchowitz, R. Canters, J. Gellermann, N. Lomax, M.b. Messmer, Ulf Lamprecht, Michael Ehmann, Hans Crezee, O. OttAbstract:Background A guideline is provided for the implementation of regional deep hyperthermia treatments under strict rules of quality assurance. The objective is to guarantee a comparable and comprehensible method in the treatment and scientific analysis of hyperthermia. The guideline describes regional deep hyperthermia (RHT) and MR-controlled partial body hyperthermia (PBH) of children, young and adult patients. According to this guideline, hyperthermia treatment is always applied in combination with chemotherapy and/or radiotherapy. Methods The guideline is based on practical experience from several hyperthermia centers. The procedure allows applying jointly coordinated standards and quality control in hyperthermia for studies. Results The guideline contains recommendations for hyperthermia treatments, including indication, preparation, treatment, and standardized analysis. Hintergrund Zur Durchführung von qualitätsgesicherten Tiefenhyperthermiebehandlungen wurde eine Leitlinie erstellt. Ziel war, ein vergleichbares und nachvollziehbares Vorgehen bei der Behandlung und der wissenschaftlichen Auswertung von Hyperthermiebehandlungen zu gewährleisten. Die Leitlinie beschreibt die „Regionale Tiefenhyperthermie“ (RHT) und die „MR-kontrollierte Teilkörperhyperthermie“ (PBH) von Kindern, jugendlichen und erwachsenen Patienten. Hyperthermie im Sinne der Leitlinie wird als Kombinationsbehandlung mit einer Chemo- und/oder Strahlentherapie durchgeführt. Methodik Die Leitlinie basiert auf praktischen Erfahrungen mehrerer Hyperthermiezentren. Dieses Vorgehens erlaubt abgestimmte Standards in der Anwendung und der Qualitätskontrolle in der Hyperthermie für Studien. Ergebnisse Diese Leitlinie enthält Empfehlungen für Hyperthermiebehandlungen mit Indikationsstellung, Vorbereitung, Durchführung und standardisierter Auswertung.